Spotlight on Eszopiclone in Insomnia
Tóm tắt
Eszopiclone (Lunesta®), the S-enantiomer of racemic zopiclone, is a nonbenzodiazepine hypnotic agent that is approved in the US as an oral, once-nightly therapy for insomnia in adults; eszopiclone is also currently under review by the European Medicines Agency. Eszopiclone is rapidly absorbed after oral administration without any next-day clinical residual effects being detected. Large, well designed trials of up to 6 months’ duration have shown that eszopiclone significantly improves both sleep onset and sleep maintenance compared with placebo in adult and elderly patients with primary insomnia. Eszopiclone for 4–8 weeks also significantly improved sleep parameters compared with placebo in patients with insomnia coexisting with other conditions that also disturb sleep (co-morbid insomnia), and improved certain measures of the co-morbid conditions to a greater extent than the standard therapies alone. Short-term eszopiclone produced improvements in daytime functioning in patients with co-morbid insomnia. Six months’ therapy in adults with primary insomnia improved daytime functioning and health-related quality of life. Eszopiclone was generally well tolerated. There was no evidence of tolerance during 12 months of treatment with this agent. On discontinuation of eszopiclone, there was no rebound insomnia or serious withdrawal effects. Well designed, comparative trials with other nonbenzodiazepine hypnotics are needed to determine its relative efficacy and tolerability. A cost-utility analysis suggested that eszopiclone is cost effective for the treatment of primary insomnia in the US. Therefore, eszopiclone is a useful therapeutic option in the management of adult and elderly patients with primary or co-morbid insomnia. Unlike most other hypnotics, eszopiclone is not limited to short-term use.
Tài liệu tham khảo
Hair PI, McCormack PL, Curran MP. Eszopiclone: a review of its use in the treatment of insomnia. Drugs 2008; 68(10): 1415–34
Lunesta® (eszopiclone) tablets 1 mg, 2 mg, 3 mg: US prescribing information. Marlborough (MA): Sepracor Inc, 2008 Feb
Blaschke G, Hempel G, Müller WE. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality 1993; 5(6): 419–21
Carlson JN, Haskew R, Wacker J, et al. Sedative and anxiolytic effects of zopiclone’s enantiomers and metabolite. Eur J Pharmacol 2001; 415(2-3): 181–9
Rosenberg R, Caron J, Roth T, et al. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 2005; 6(1): 15–22
Boyle J, Trick L, Johnsen S, et al. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol. Epub 2008 Mar 18
Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20(12): 1979–91
Maier G, Koch P, Caron J, et al. Dose proportionality and time to steady-state of eszopiclone in healthy adult volunteers following single and multiple dosing [abstract no. M1325]. AAPS PharmSci 2003; 5 (4)
Fernandez C, Alet P, Davrinche C, et al. Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. J Pharm Pharmacol 2002; 54(3): 335–40
Anderson AJ, Maier G, Skolly SM. Pharmacokinetic interaction between eszopiclone and ketoconazole in healthy volunteers at steady state [abstract no. 137]. Pharmacotherapy 2005; 25(3): 474
Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007 Aug 1; 30(8): 959–68
Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26(7): 793–9
Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005; 28(6): 720–7
McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006; 22(9): 1633–42
Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59(11): 1052–60
Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008 May; 65(5): 551–62
Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006; 108(6): 1402–10
Rubens R, Wessel T, Caron J, et al. The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia [abstract no. P02.014]. Neurology 2006; 66(5 Suppl. 2): 78–79. Plus poster presented at the 58th Annual Meeting of the American Academy of Neurology; 2006 Apr 1–8; San Diego (CA)
Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6(6): 487–95
Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007; 3(1): 48–55
Botteman MF, Ozminkowski RJ, Wang S, et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model [published erratum appears in CNS Drugs 2007; 21 (5): 405]. CNS Drugs 2007; 21(4): 319–34